Sugi Predict

Sugi Predict / Compounds / SCHEMBL762294

SCHEMBL762294

SCHEMBL762294

CN[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.46
▸ USP30 Q70CQ3 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ NAMPT P43490 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ PDE4B Q07343 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ PTPN2 P17706 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ PTPN6 P29350 1/20 0.37
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391518 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL3567347 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL19881453 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL13282934 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL14303516 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL12458213 0.89 NR1H2 (0.45) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL31084556 0.86 EPHX1 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL18502917 0.86 EPHX1 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL20121454 0.86 EPHX1 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL24098660 0.85 NR1H2 (0.45) NR1H2USP30USP2SMN1; SMN2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2025-11-20 — — US disclosed
US-20250340548-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORP (US) 2025-11-06 — — US disclosed
US-12291539-B2 KRAS G12C inhibitors FRONTIER MEDICINES CORPORATION (US) 2025-05-06 — — US disclosed
EP-4536224-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE Blossomhill Therapeutics, Inc. (US) 2025-04-16 — — EP disclosed
US-20250019387-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION 2025-01-16 — — US disclosed
EP-4426695-A1 KRAS G12C INHIBITORS Frontier Medicines Corporation (US) 2024-09-11 — — EP disclosed
WO-2023081840-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION (US) 2023-05-11 — — WO disclosed
WO-2023081840-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION (US) 2023-05-11 — — WO disclosed
US-9969730-B2 Stable SNS-595 compositions and methods of preparation SUNESIS PHARMACEUTICALS, INC. (US) 2018-05-15 — — US disclosed
EP-3299358-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2018-03-28 — — EP disclosed
US-8497282-B2 Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid SUNESIS PHARMACEUTICALS, INC. (US) 2013-07-30 — — US disclosed
US-8138202-B2 Stable SNS-595 compositions and methods of preparation SUNESIS PHARMACEUTICALS, INC. (US) 2012-03-20 — — US disclosed
US-20110086876-A1 STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION SUNESIS PHARMACEUTICALS, INC. 2011-04-14 — — US disclosed
US-20110082169-A1 Stable SNS-595 Compositions and Methods of Preparation SUNESIS PHARMACEUTICALS, INC. 2011-04-07 — — US disclosed
US-20100203162-A1 Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid SUNESIS PHARMACEUTICALS, INC. 2010-08-12 — — US disclosed
WO-2010078294-A1 METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID SUNESIS PHARMACEUTICAL, INC. (US) 2010-07-08 — — WO disclosed
US-7728131-B2 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia NIPPON SHINYAKU CO., LTD. (JP) 2010-06-01 — — US disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 — — US disclosed
US-20080293940-A1 Amide Derivative and Medicine NIPPON SHINYAKU CO., LTD. (JP) 2008-11-27 — — US disclosed
EP-1702917-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2006-09-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082169-A1 Stable SNS-595 Compositions and Methods of Preparation NES, NCDN, NCL NR1H2 3143/4885USP30 3770/4885USP2 3786/4885
US-20100203162-A1 Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid CYP7A1, MT-ND1, DNM1 NR1H2 1541/4885USP30 4818/4885USP2 4595/4885
US-20090312310-A1 Imidazothiazole derivatives TP53, MDM2, TP53BP1 NR1H2 4156/4885USP30 1285/4885USP2 848/4885
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE AADAC, PAICS, CYP3A43 NR1H2 1691/4885USP30 4374/4885USP2 4088/4885
US-20110086876-A1 STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION NES, NCDN, NCL NR1H2 3143/4885USP30 3770/4885USP2 3786/4885
US-12291539-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS NR1H2 2175/4885USP30 1382/4885USP2 953/4885
US-20250340548-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 2175/4885USP30 1382/4885USP2 953/4885
US-20080293940-A1 Amide Derivative and Medicine ABL2, ABL1, BCR NR1H2 853/4885USP30 2538/4885USP2 1714/4885
US-20250019387-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 2175/4885USP30 1382/4885USP2 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.